U.S. Markets closed

Celsius Holdings, Inc. (CELH)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
57.81+1.23 (+2.17%)
At close: 4:00PM EDT

57.75 -0.06 (-0.10%)
After hours: 5:10PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close56.58
Open56.47
Bid57.50 x 900
Ask58.00 x 1100
Day's Range56.02 - 58.49
52 Week Range3.90 - 70.66
Volume470,981
Avg. Volume1,564,863
Market Cap4.196B
Beta (5Y Monthly)2.10
PE Ratio (TTM)525.55
EPS (TTM)0.11
Earnings DateMar 11, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est59.75
  • Hain Celestial (HAIN) Up 68% in a Year on Transformation Gains
    Zacks

    Hain Celestial (HAIN) Up 68% in a Year on Transformation Gains

    Hain Celestial (HAIN) is gaining from transformation efforts. The company is focused on making investments in key brands while exiting non-strategic brands.

  • Why Celsius Holdings Stock Fell 19% in March
    Motley Fool

    Why Celsius Holdings Stock Fell 19% in March

    Shares of beverage company Celsius Holdings (NASDAQ: CELH) fell 19.3% in March, according to data provided by S&P Global Market Intelligence. On March 11, Celsius reported financial results for 2020. To be fair, fourth-quarter revenue showed a sequential decline -- third-quarter revenue was $36.8 million, whereas Q4 revenue was $35.7 million.

  • How Jonah Lupton Expects TransMedics Group Stock To React To FDA Decision
    Benzinga

    How Jonah Lupton Expects TransMedics Group Stock To React To FDA Decision

    Jonah Lupton of Lupton Capital was focused on TransMedics Group Inc (NASDAQ: TMDX) Tuesday. The Nasdaq halted trading in TransMedics stock while the FDA reviews the company's OCS Heart System. If the FDA panel votes against approval, it's not the end of the story, Lupton told Benzinga "Power Hour" host Luke Jacobi. Lupton Talks TransMedics: Lupton expects the stock to open 15%-20% lower on Wednesday if the FDA news is negative, he told Jacobi. If the panel votes yes, Lupton said he expects the stock to be up at least 20%-25% on Wednesday. "If approval comes, I think this is a $55-$60 stock in the next month-and-a-half," he said. Lupton's Take On Celsius Holdings: Jacobi said he had the chance to try a Celsius Holdings Inc (NASDAQ: CELH) beverage and asked Lupton if he had any thoughts on Celsius from an investment standpoint. The stock sold off after fourth-quarter earnings, and Lupton attributes the stock move to supply that could not meet demand for the product. Celsisus is No. 2 on Amazon.com Inc (NASDAQ: AMZN) for the entire energy drink category and would probably be No. 1 if it wasn't running out of supply, Lupton said. "It's not just a growth stock. It's also a reopening stock." Lupton also discussed Upstart Holdings Inc (NASDAQ: UPST). "This stock kind of saved my portfolio" in the second quarter, he said. The stock was at $56 when Upstart reported fourth-quarter earnings and raised guidance for 2021 from about $360 million in revenue to $500 million in revenue and announced an aquisition of Prodigy Software. The stock nearly tripled in about a week on the news. CELH, TMDX, UPST Price Action: Celsius Holdings gained 0.89% Tuesday, closing at $52.37. TransMedics Group was halted at $34.52 on Tuesday. Upstart gained 2.69%, closing at $144.30. Image by Lorenzo Cafaro from Pixabay. See more from BenzingaClick here for options trades from BenzingaTopps In 'The Same Financial Position As Disney Was In 1984,' Eisner SaysWhy This GM, Ford Analyst Is Bullish On The Motor City Automakers© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.